CoChat
Sign Up
Cited by 33Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatmentAdvanced Neuroimaging Techniques and Applications

Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network

Open access
Darlix, Amélie, Mandonnet, Emmanuel, Freyschlag, Christian F, Pinggera, Daniel, Forster, Marie-Therese, Voss, Martin, Steinbach, Joachim, Loughrey, Carmel +17 more·2019·Neuro-Oncology Practice
DOI 10.1093/nop/npy051PMC PMC6660823
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial. Methods: An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients. Results: The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression. Conclusions: The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nop/npy051

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Temozolomide is an alkylating lipophilic agent that crosses the blood-brain barrier to treat GBM.

    “Temozolomide is an alkylating lipophilic agent that crosses the BBB to treat GBM36,37.”

    From Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system (2025) · cites this paper as [36]

    The Abstract (Conclusions; page unavailable) identifies temozolomide as a chemotherapy drug, and the Discussion (Choice of Chemotherapy Regimen; page unavailable) reports its use and efficacy in diffuse low-grade gliomas. The paper does not establish that it is lipophilic or alkylating, crosses the blood–brain barrier, or is used to treat GBM; those parts of the claim are unsupported by this copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 56

  1. [1]Louis DN, Perry A, Reifenberger G et al The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131(6): 803– 820. 27157931
  2. [2]Capelle L, Fontaine D, Mandonnet E et al Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013; 118(6): 1157– 1168. 23495881
  3. [3]Mandonnet E, Delattre JY, Tanguy ML et al Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003; 53(4): 524– 528. 12666121
  4. [4]Buckner JC, Shaw EG, Pugh SL et al Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016; 374(14): 1344– 1355. 27050206 PMC5170873
  5. [5]Jakola AS, Skjulsvik AJ, Myrmel KS et al Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017; 28(8): 1942– 1948. 28475680 PMC5834105
  6. [7]Duffau H Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien). 2016; 158(1): 51– 58. 26530708
  7. [8]Soffietti R, Baumert BG, Bello L et al Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010; 17(9): 1124– 1133. 20718851
  8. [9]Duffau H, Taillandier L New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualized therapeutic approach. Neuro Oncol. 2015; 17(3): 332– 342. 25087230 PMC4483091
  9. [10]Laack NN, Sarkaria JN, Buckner JC Radiation Therapy Oncology Group 9802: controversy or consensus in the treatment of newly diagnosed low-grade glioma? Semin Radiat Oncol. 2015; 25(3): 197– 202. 26050590 PMC5434758
  10. [11]Field KM, Rosenthal MA, Khasraw M Sawkins K Nowak AK Evolving management of low grade glioma: No consensus amongst treating clinicians. J Clin Neurosci. 2016; 23: 81– 87. 26601811
  11. [12]Weller M, van den Bent M, Tonn JC et al European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18(6): e315– e329. 28483413
  12. [13]The European Low-Grade Glioma Network. Evidence-based management of adult patients with diffuse glioma. Lancet Oncol 2017; 18(8): e429. 28759376
  13. [14]Rudà R, Soffietti R Controversies in management of low-grade gliomas in light of new data from clinical trials. Neuro Oncol. 2017; 19(2): 143– 144. 28391299 PMC5464130
  14. [15]Mandonnet E, Duffau H An attempt to conceptualize the individual onco-functional balance: why a standardized treatment is an illusion for diffuse low-grade glioma patients. Crit Rev Oncol Hematol. 2018; 122: 83– 91. 29458793
  15. [16]Chamberlain MC Does RTOG 9802 change practice with respect to newly diagnosed low-grade glioma? J Clin Oncol. 2013; 31(5): 652– 653. 23295807
  16. [17]Chang EF, Clark A, Jensen RL et al Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg. 2009; 111(2): 203– 210. 19267536
  17. [18]Daniels TB, Brown PD, Felten SJ et al Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 2011; 81(1): 218– 224. 21549518 PMC3151343
  18. [19]Brada M, Viviers L, Abson C et al Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003; 14(12): 1715– 1721. 14630674
  19. [20]Hoang-Xuan K, Capelle L, Kujas M et al Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004; 22(15): 3133– 3138. 15284265
  20. [21]Kaloshi G, Benouaich-Amiel A, Diakite F et al Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007; 68(21): 1831– 1836. 17515545
  21. [22]Ricard D, Kaloshi G, Amiel-Benouaich A et al Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007; 61(5): 484– 490. 17469128
  22. [23]Soffietti R, Rudà R, Bradac GB Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998; 43(5): 1066– 1073. 9802850
  23. [24]Peyre M, Cartalat-Carel S, Meyronet D et al Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010; 12(10): 1078– 1082. 20488959 PMC3018918
  24. [26]Mandonnet E, Wager M, Almairac F, et al Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step? Neurooncol Pract. 2017; 4(4): 241– 247. PMC6655513 31386020
  25. [27]Rofes A, Mandonnet E, Godden J et al Survey on current cognitive practices within the European Low-Grade Glioma Network: towards a European assessment protocol. Acta Neurochir (Wien). 2017; 159(7): 1167– 1178. 28474122
  26. [28]Spena G, Schucht P, Seidel K et al Brain tumors in eloquent areas: a European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis. Neurosurg Rev. 2017; 40(2): 287– 298. 27481498
  27. [29]Freyschlag CF, Krieg SM, Kerschbaumer J, et al Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging [published online ahead of print July 10, 2018]. J Neurooncol. doi: 10.1007/s11060-018-2916-3. PMC6132968 29992433 · DOI
  28. [30]Blonski M, Taillandier L, Herbet G et al Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012; 106(2): 353– 366. 21785913
  29. [31]Blonski M, Pallud J, Gozé C et al Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients. J Neurooncol. 2013; 113(2): 267– 275. 23479036
  30. [32]Jo J, Williams B, Smolkin M et al Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma. J Neurooncol. 2014; 120(1): 155– 161. 25038848
  31. [33]Di Carlo DT, Duffau H, Cagnazzo F, Benedetto N, Morganti R, Perrini P IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta- analysis [published online ahead of print June 26, 2018]. Neurosurg Rev. doi: 10.1007/s10143-018-0996-3. 29943141 · DOI
  32. [35]van den Bent MJ, Afra D, de Witte O et al Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366(9490): 985– 990. 16168780
  33. [36]Douw L, Klein M, Fagel SS et al Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009; 8(9): 810– 818. 19665931
  34. [38]Baumert BG, Hegi ME, van den Bent MJ et al Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016; 17(11): 1521– 1532. 27686946 PMC5124485
  35. [39]van den Bent MJ, Baumert B, Erridge SC et al Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017; 390(10103): 1645– 1653. 28801186 PMC5806535
  36. [40]Jhaveri J, Liu Y, Chowdhary M et al Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: an analysis of the National Cancer Data Base. Cancer. 2018; 124(6): 1169– 1178. 29205287
  37. [41]Wu J, Neale N, Huang Y et al Comparison of adjuvant radiation therapy alone and chemotherapy alone in surgically resected low-grade gliomas: survival analyses of 2253 cases from the National Cancer Data Base. World Neurosurg. 2018; 112: e812– e822. 29409888
  38. [42]Wahl M, Phillips JJ, Molinaro AM et al Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017; 19(2): 242– 251. 27571885 PMC5464133
  39. [43]Bady P, Kurscheid S, Delorenzi M et al The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol. 2018; 135(4): 601– 615. 29368212 PMC5978935
  40. [44]Taal W, van der Rijt CC, Dinjens WN et al Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. J Neurooncol. 2015; 121(2): 365– 372. 25344884
  41. [45]Wick W, Roth P, Hartmann C et al Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016; 18(11): 1529– 1537. 27370396 PMC5063521
  42. [46]Brada M, Stenning S, Gabe R et al Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010; 28(30): 4601– 4608. 20855843
  43. [47]van den Bent MJ, Wefel JS, Schiff D et al Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011; 12(6): 583– 593. 21474379
  44. [48]Schmitt P, Mandonnet E, Perdreau A, Angelini ED Effects of slice thickness and head rotation when measuring glioma sizes on MRI: in support of volume segmentation versus two largest diameters methods. J Neurooncol. 2013; 112(2): 165– 172. 23397270
  45. [49]Mandonnet E, Pallud J, Clatz O et al Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev. 2008; 31(3): 263– 269. 18299912
  46. [50]Jakola AS, Moen KG, Solheim O Kvistad KA. “No growth” on serial MRI scans of a low grade glioma? Acta Neurochir (Wien). 2013; 155(12): 2243– 2244. 24146183
  47. [51]Pallud J, Llitjos JF, Dhermain F et al Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2012; 14(4): 496– 505. 22416109 PMC3309865
  48. [52]Ben Abdallah M, Blonski M, Wantz-Mezieres S Gaudeau Y Taillandier L Moureaux JM. Statistical evaluation of manual segmentation of a diffuse low-grade glioma MRI dataset. Conf Proc IEEE Eng Med Biol Soc. 2016; 2016: 4403– 4406. 28269254
  49. [53]Prodhomme O, Seguret F, Martrille L, et al Organ volume measurements: comparison between MRI and autopsy findings in infants following sudden unexpected death. Arch Dis Child Fetal Neonatal Ed. 2012; 97(6): F434– F438. 22447988
  50. [54]Liu R, Solheim K, Polley MY et al Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009; 11(1): 59– 68. 18713953 PMC2718960
  51. [55]Reijneveld JC, Taphoorn MJ, Coens C et al Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016; 17(11): 1533– 1542. 27686943
  52. [56]Fountain DM, Allen D, Joannides AJ Nandi D, Santarius T, Chari A. Reporting of patient-reported health-related quality of life in adults with diffuse low-grade glioma: a systematic review. Neuro Oncol. 2016; 18(11): 1475– 1486. 27194147 PMC5063520
  53. [57]Boele FW, Zant M, Heine EC et al The association between cognitive functioning and health-related quality of life in low-grade glioma patients. Neurooncol Pract. 2014; 1(2): 40– 46. 26034615 PMC4371165
  54. [58]Prabhu RS, Won M, Shaw EG et al Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol. 2014; 32(6): 535– 541. 24419119 PMC3918537
  55. [59]Klein M Treatment options and neurocognitive outcome in patients with diffuse low-grade glioma. J Neurosurg Sci. 2015; 59(4): 383– 392. 26375636
  56. [60]Habets EJ, Taphoorn MJ, Nederend S et al Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J Neurooncol. 2014; 116(1): 161– 168. 24162809

Cited by

Sorted by citations

Authors
Darlix, A., Mandonnet, E., Freyschlag, C. F., Pinggera, D., Forster, M.-T., Voss, M., Steinbach, J., Loughrey, C., Goodden, J., Banna, G., Di Blasi, C., Foroglou, N., Hottinger, A. F., Baron, M.-H., Pallud, J., Duffau, H., Rutten, G.-J., Almairac, F., Fontaine, D., Taillandier, L., Pessanha Viegas, C., Albuquerque, L., von Campe, G., Urbanic-Purkart, T., & Blonski, M.
Affiliations
  • Université de Montpellier (FR)
  • Hôpital Lariboisière (FR)
  • Innsbruck Medical University (AT)
  • Department of Neurosurgery, Goethe University Hospital, Frankfurt, Germany
  • University Hospital Frankfurt (DE)
  • Leeds General Infirmary (GB)
  • Ospedale Cannizzaro (IT)
  • Department of Neurosurgery and Gammaknife, Cannizzaro General Hospital, Catania, Italy
  • Aristotle University of Thessaloniki, Department of Neurosurgery, AHEPA University Hospital, Greece
  • Centre Hospitalier Universitaire Vaudois (CH)
  • Centre Hospitalier Universitaire de Besançon (FR)
  • Sorbonne Paris Cité (FR)
  • Inserm (FR)
  • Elisabeth-TweeSteden Ziekenhuis (NL)
  • Centre Hospitalier Universitaire de Nice (FR)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • Hospital Garcia de Orta, Almada, Portugal
  • Department of Neurosurgery, Medical University of Graz, Austria
  • Medical University of Graz (AT)
Corresponding author
Darlix, Amélie
ORCID
Venue
Neuro-Oncology Practice
Publisher
Oxford University Press (OUP)
Published
2018-12-13
Volume
6
Issue
4
Pages
264-273
ISSN
  • 2054-2577 (ISSN-L)
  • 2054-2585
DOI
10.1093/nop/npy051
PMC
PMC6660823
OpenAlex
W2904737739
Cited by
33
References
3
Citations by year
2026: 1 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 3 · 2021: 5 · 2020: 8
FWCI
1.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuro-Oncology Practice (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by-nc)
  • IRIS (submittedVersion, cc-by-nc)
  • HAL (submittedVersion)
  • Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced Neuroimaging Techniques and Applications
Keywords
diffuse low-grade glioma, chemotherapy, temozolomide, procarbazine, lomustine, and vincristine, radiotherapy, postoperative care, treatment effect heterogeneity, pediatric brain tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review